XTalks

AUGUST 18, 2020

The study was funded by a clinical research agreement with the NBA and the players’ union – the National Basketball Players Association (NDG) – which together, contributed over $500,000 to fund the Yale study. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genomics 90

XTalks

NOVEMBER 7, 2022

“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

SEPTEMBER 4, 2024

Alnylam Pharmaceuticals announced promising results from its HELIOS-B Phase III clinical trial evaluating vutrisiran, an investigational RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). As of March 2024, the FDA has approved six small interfering RNA (siRNA) therapies.

Trials 52

Trials RNA Protein Gene Editing 52

XTalks

JUNE 18, 2024

XTALKS CLINICAL EDGE: Issue 2 — Elixirgen Therapeutics’ Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials.

Protein 52

Protein RNA Genetics Gene Expression 52

XTalks

AUGUST 18, 2023

Khanani, director of clinical research at Sierra Eye Associates, Reno, Nevada, in Iveric Bio’s news release. RELATED: Apellis’ Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical Benefit What Is Geographic Atrophy? How Does Izervay Work?

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 27, 2025

Related: Iovebi (Inavolisib) Gains FDA Nod for PIK3CA-Mutated HR-Positive, HER2-Negative Breast Cancer Given the role of ESR1 , Bio-Techne launched a highly sensitive ESR1 mutation monitoring assay in December 2024 to track these mutations in ctDNA and exosomal RNA, helping to catch signs of resistance early on.

Trials 59

Trials HR Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 20, 2025

Breakthroughs and Advances in Rare Disease Research Recent advances in rare disease research are ushering in transformative therapies for longstanding unmet needs. In hereditary angioedema (HAE), for example, donidalorsen an investigational RNA-targeted prophylactic treatment has demonstrated impressive efficacy.

Gene Therapy 59

Gene Therapy Gene Research Genetics 59

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. Addressing the Rapidly Evolving Vaccine Development Landscape.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92